Voyager Therapeutics Inc (VYGR) — Cash Flow-to-Debt Ratio
Voyager Therapeutics Inc (VYGR) has a Cash Flow-to-Debt Ratio of -0.45x as of September 2025, meaning its operating cash flow of $-31.05 Million could theoretically repay 0% of its total liabilities ($68.49 Million) in one year. See Voyager Therapeutics Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Voyager Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Voyager Therapeutics Inc across 12 annual periods. For the full cash flow conversion analysis, see Voyager Therapeutics Inc (VYGR) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Voyager Therapeutics Inc (2013–2024)
Year-by-year debt coverage analysis for Voyager Therapeutics Inc. Check Voyager Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.16x | $-15.31 Million | $93.29 Million | ▼ -124.2% |
| 2023 | 0.68x | $77.92 Million | $114.96 Million | ▲ +643.7% |
| 2022 | -0.12x | $-12.51 Million | $100.34 Million | ▲ +77.0% |
| 2021 | -0.54x | $-53.52 Million | $98.80 Million | ▲ +39.9% |
| 2020 | -0.90x | $-96.72 Million | $107.26 Million | ▼ -572.9% |
| 2019 | 0.19x | $48.67 Million | $255.25 Million | ▲ +256.7% |
| 2018 | -0.12x | $-15.89 Million | $130.58 Million | ▲ +90.0% |
| 2017 | -1.22x | $-61.35 Million | $50.43 Million | ▼ -53.6% |
| 2016 | -0.79x | $-42.48 Million | $53.64 Million | ▼ -215.8% |
| 2015 | 0.68x | $41.30 Million | $60.38 Million | ▲ +159.4% |
| 2014 | -1.15x | $-11.92 Million | $10.35 Million | ▲ +15.9% |
| 2013 | -1.37x | $-5.45 Million | $3.98 Million | — |